Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.

Autor:	Atkins, Michael B1 mba41@georgetown.edu, Plimack, Elizabeth R2, Puzanov, Igor3,4, Fishman, Mayer N5, McDermott, David F6, Cho, Daniel C7, Vaishampayan, Ulka8, George, Saby4, Olencki, Thomas E9, Tarazi, Jamal C10, Rosbrook, Brad10, Fernandez, Kathrine C11, Lechuga, Mariajose12, Choueiri, Toni K13
Zdroj:	Lancet Oncology. Mar2018, Vol. 19 Issue 3, p405-415. 11p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu